COVID-19 Updates: What We Know Now

Newest Episodes:
• To Mask or Not to Mask as Part of Standard Precautions?
TUNE IN TO THE SHEA JOURNALS PODCASTS

AVAILABLE ON:

iHeartRadio
Spotify
Apple Podcasts
SoundCloud
Stitcher

Safe healthcare for all
With funding from the Centers for Disease Control and Prevention, IDSA has launched the COVID-19 Real Time Learning Network, an online community that brings together information and opportunities for discussion on latest research, guidelines, tools and resources from a variety of medical subspecialties around the world.

www.COVID19LearningNetwork.org
@RealTimeCOVID19 | #RealTimeCOVID19
An online learning module designed with frontline healthcare personnel in mind.

PreventionCHKC.org
ICHE Journal – Fast Tracking COVID Article Submissions

Infection Control & Hospital Epidemiology publishes scientifically authoritative, clinically applicable, peer-reviewed research on control and evaluation of the transmission of pathogens in healthcare institutions and on the use of epidemiological principles and methods to evaluate and improve the delivery of care. Major topics covered include infection control practices, surveillance, antimicrobial stewardship, cost-benefit analyses, resource use, occupational health, and regulatory issues.

www.cambridge.org/iche

SAFE HEALTHCARE FOR ALL
ASHE JOURNAL

High quality articles across the full spectrum of antimicrobial stewardship and healthcare epidemiology.

Exceptional author experience through constructive peer review, competitive turnaround times, immediate online publication, a streamlined production process, and social media promotion.

Global, open access journal, bringing the widest possible impact, reach and discoverability of your research.

www.cambridge.org/ashe
SHEA Webinar

COVID-19 Town Hall
Round 91

Music:
www.bensound.com
House Keeping Items

- Technical difficulties? Visit: https://support.zoom.us
- Webinar recording, PowerPoint presentation, and references available LearningCE’s Rapid Response Program
- Streaming Live on SHEA's Facebook page
- Zoom Q&A and Chat
SHEA Town Hall 91
Overview
SARS-CoV-2 Variants, US, CDC

Data from 5/28 – 9/16 2023

https://covid.cdc.gov/covid-data-tracker/#variant-proportions

Data from 6/25 – 10/14 2023
US COVID-19 HOTSPOTS

February 6, 2022

July 22, 2023

September 23, 2023

October 22, 2023

COVID-19 WASTEWATER SURVEILLANCE

[Map showing wastewater surveillance across the United States with data on SARS-CoV-2 virus levels by site, United States.

Hospitalizations unchanged from our last Town Hall
ICU admissions decreased by 1.9% from our last Town Hall

COVID-19 DAILY HOSPITAL ADMISSIONS IN THE UNITED STATES, BY AGE

Data from 9/12, 2023

Data from 10/22, 2023

Daily hospitalizations decreased by 4.5% from our last Town Hall

Source: New York Times 10-21-2023
COVID-19 Deaths in the United States

Cumulative Deaths – 1,143,192

52.2% decreased from our last Town Hall

INFLUENZA ACTIVITY BY STATE IN THE UNITED STATES

Source: CDC https://www.cdc.gov/flu/weekly/usmap.htm 10-22-23
Percentage of Outpatient Visits for Influenza-Like Illness

This Month’s Emerging Infectious Disease News


2. A randomized controlled trial published in *The New England Journal of Medicine* showed that treatment with inhaled fluticasone furoate for 14 days did not result in a shorter time to recovery than placebo among outpatients with COVID-19.

3. A *JAMA Network Open* study demonstrated that high-flow nasal oxygen and noninvasive ventilation appear not to be aerosol-generating procedures.

4. A large *JAMA Network Open* retrospective cohort study, found that COVID-19 was associated with a substantial risk for the subsequent development of autoimmune and autoinflammatory connective tissue disorders.

5. A *JAMA Internal Medicine* study of US Veterans found that COVID-19 survivors had no clinically significant excess hazard of death greater than comparators among those who survived at least 6 months after infection.

6. A *JAMA* study found that that long-term support for family members of ICU patients with COVID-19 ARDS should be the same as for relatives of patients with other causes of ARDS.

7. A *Lancet Public Health* paper provided a retrospective assessment of COVID surveillance systems used in England during the pandemic, concluding that deploying a suite of monitoring systems is optimal.

References available in the chat
8. Another *Lancet* paper reported on the comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab for preventing severe COVID-19 outcomes in non-hospitalized high-risk patients during Omicron, finding approximately equivalent outcomes for both.

9. An opinion piece in *The Journal of Infectious Diseases* presents evidence that so-called ‘hybrid immunity’ (i.e., vaccination plus infection) produces more robust immunity than either alone.

10. A paper in *Clinical Infectious Diseases* found that in a highly immune adult population, median SARS-CoV-2 viral loads peaked around the fourth day of symptoms and that Influenza A viral loads peaked soon after symptom onset.

11. A short *Clinical Infectious Diseases* opinion piece written by a fellow in infectious diseases describes his grieving process during the pandemic in part stimulated by his struggles with close family members who routinely reported their anti-science beliefs and conspiracy theories about COVID.

12. A paper in *Infection Control and Hospital Epidemiology* found that an immediate, substantial, and sustained increase of healthcare-associated respiratory viral infections occurred after the institution discontinued universal masking.

13. The *U.S. Food and Drug Administration* amended the emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, Adjuvanted to include the 2023-2024 formula for anyone 12 years of age and older.

14. The *NIAID* is beginning a clinical trial of a “Universal” influenza vaccine.

References available in the chat
Panelists:

Dr. David Henderson  
*NIH Consultant*

Dr. Sarah Haessler  
*Baystate Health*

Dr. Kristina Bryant  
*University of Louisville*

Dr. David Weber  
*UNC School of Medicine*
COVID-19 UPDATE:
RISKS TO PREGNANT PERSONS AND THEIR CHILDREN
& COVID-19 VACCINE AND SAFETY

David J. Weber, MD, MPH, FIDSA, FSHEA, FRSM (London)
Sanders Distinguished Professor of Medicine, Pediatrics and Epidemiology
Associate Chief Medical Officer, UNC-MC
Medical Director, Hospital Epidemiology, UNC-MC
University of North Carolina, Chapel Hill, NC

Disclosures: Consultancy; Pfizer, PDI, BD, Germitec, GAMA
All drugs/vaccines issues discussed consistent with FDA approvals or authorizations
Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection: an individual participant data meta-analysis

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Studies (n)</th>
<th>Included studies*</th>
<th>Symptomatic RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICU admission</td>
<td>8</td>
<td>abcdefg</td>
<td>4.88 (2.57 to 9.27)</td>
</tr>
<tr>
<td>Ventilation</td>
<td>7</td>
<td>abcdefg</td>
<td>24.09 (8.85 to 64.77)</td>
</tr>
<tr>
<td>Critical care</td>
<td>7</td>
<td>abcdefg</td>
<td>8.47 (3.37 to 21.28)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>6</td>
<td>abcdefg</td>
<td>34.58 (3.38 to 356.1)</td>
</tr>
<tr>
<td>Maternal death</td>
<td>10</td>
<td>abcdefghij</td>
<td>8.48 (1.70 to 42.21)</td>
</tr>
<tr>
<td>Haemorrhage</td>
<td>6</td>
<td>abcdefg</td>
<td>1.30 (0.81 to 2.10)</td>
</tr>
<tr>
<td>Placental abruption</td>
<td>5</td>
<td>abcdefg</td>
<td>2.08 (0.25 to 4.63)</td>
</tr>
</tbody>
</table>

**Table 4 Relative risk of outcomes comparing COVID-19 cases (symptomatic cases only) versus COVID-negative pregnancies**

**WHAT IS ALREADY KNOWN ON THIS TOPIC**
- Despite the ballooning literature regarding SARS-CoV-2 infection during pregnancy, it is difficult to synthesise the information and evaluate the overall quality of evidence given the heterogeneity in study design, selection of comparison groups, methods for assessing infection, population-specific baseline risks and definitions of key outcomes.
- Prior reviews based on published data have included limited data from low-income countries.

**WHAT THIS STUDY ADDS**
- We established plans for a sequential, prospective meta-analysis in April 2020 with a goal of better understanding the excess risks—or lack thereof—of COVID-19 during pregnancy.
- This individual participant data meta-analysis of unpublished and published data from a dozen studies includes more than 13,000 pregnant women and shows that COVID-19 during pregnancy increases the risk of maternal mortality, intensive care unit admission, receiving mechanical ventilation, receiving any critical care or being diagnosed with pneumonia or thromboembolic disease.
- Infants born to infected pregnant women were more likely to be admitted to the neonatal intensive care unit and to be born prematurely.
- In contrast to other reviews, we did not find any link between SARS-CoV-2 infection during pregnancy and an increased risk of stillbirth at or beyond 28 weeks' gestation, nor any link with intrauterine growth restriction.
- Further, we include the first large set of pregnancy cohort data from sub-Saharan Africa.

**HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY**
- Global guidance has been equivocal on the potential risks of infection and benefits and safety of vaccination, and more than 80 countries do not currently recommend that all pregnant and lactating women should be vaccinated.
- Given the clear and consistent findings regarding the risk of COVID-19 infection during pregnancy, global effort to improve access to safe preventives and therapeutics is an urgent priority.
Comparison of Maternal and Neonatal Outcomes between SARS-CoV-2 Variants: A Retrospective, Monocentric Study

This retrospective, monocentric study aimed to fill this knowledge gap by analyzing the outcomes of pregnant women with acute SARS-CoV-2 infection caused by the Alpha, Delta, and Omicron variants. The study, conducted between December 2020 and March 2022 at San Marco Hospital, included 313 pregnant women with confirmed SARS-CoV-2 infection. The results showed that the Delta variant was associated with a significantly higher incidence of adverse outcomes, such as premature births, maternal intensive care unit admission, intrauterine growth restriction, and small for gestational age infants. Additionally, the Delta variant was linked to lower Apgar scores, higher maternal and fetal mortality rates, and increased levels of various biomarkers indicating more severe illness. Finally, the Delta variant also presented a greater possibility of vertical transmission.

SARS-CoV-2 infection and COVID-19 vaccination in pregnancy

Fig. 1 | Direct versus indirect effects of SARS-CoV-2 infection on the fetus and placenta. Maternal SARS-CoV-2 infection can impact pregnancy in numerous ways. The need for intensive care associated with severe disease can necessitate delivering the infant, causing an increased rate of preterm delivery. Placental infection can be associated with SARS-CoV-2 placenitis, which is associated with an increased risk of stillbirth. Even in the absence of placental infection, inflammatory changes are observed in the decidua and placenta, and these may be linked to the increased risk of pre-eclampsia associated with SARS-CoV-2 infection in pregnancy. SARS-CoV-2 can also be vertically transmitted to the fetus, although this is uncommon. Blue indicates indirect outcomes on the fetus and placenta associated with maternal infection with SARS-CoV-2, whereas red indicates outcomes associated with direct fetal infection.

Table 1 | Epidemiological studies on the safety of COVID-19 vaccination in pregnancy

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of participants vaccinated in pregnancy</th>
<th>Country</th>
<th>Approach</th>
<th>Outcomes examined</th>
<th>Impact of COVID-19 vaccination</th>
</tr>
</thead>
<tbody>
<tr>
<td>v-safe pregnancy registry</td>
<td>5,006</td>
<td>United States</td>
<td>Registry</td>
<td>Stillbirth, preterm birth (PTB), small for gestational age (SGA), neonatal death, congenital abnormalities</td>
<td>None detected</td>
</tr>
<tr>
<td>Stock et al. 2022</td>
<td>18,199</td>
<td>Scotland</td>
<td>Registry</td>
<td>PTB, preterm birth, SGA, neonatal death, congenital abnormalities</td>
<td>None detected</td>
</tr>
<tr>
<td>Bookstein Peretz et al. 2021</td>
<td>380</td>
<td>Israel</td>
<td>Registry</td>
<td>Miscarriage, PTB, SGA, NICU admission</td>
<td>None detected</td>
</tr>
<tr>
<td>Norwegian National Health Registers</td>
<td>1,003</td>
<td>Norway</td>
<td>Case-control</td>
<td>Miscarriage</td>
<td>None detected</td>
</tr>
<tr>
<td>Vaccine Safety Datalink</td>
<td>31,080</td>
<td>USA</td>
<td>Case-control</td>
<td>Stillbirth</td>
<td>None detected</td>
</tr>
<tr>
<td>Weinroth et al. 2021</td>
<td>913</td>
<td>Israel</td>
<td>Cohort</td>
<td>Miscarriage, PTB, SGA</td>
<td>None detected</td>
</tr>
<tr>
<td>Blakey et al. 2021</td>
<td>140</td>
<td>England</td>
<td>Cohort</td>
<td>Miscarriage, PTB, SGA, NICU admission, congenital abnormalities</td>
<td>None detected</td>
</tr>
<tr>
<td>MacCabe Healthcare Services</td>
<td>24,288</td>
<td>Israel</td>
<td>Cohort</td>
<td>Miscarriage, PTB, SGA, pre-eclampsia, SARS-CoV-2 infection</td>
<td>Reduced risk of COVID-19 infection</td>
</tr>
<tr>
<td>Thaler et al. 2021</td>
<td>140</td>
<td>United States</td>
<td>Cohort</td>
<td>Miscarriage, PTB, SGA, pre-eclampsia, SARS-CoV-2 infection</td>
<td>None detected</td>
</tr>
<tr>
<td>UK Health Security Agency</td>
<td>58,116</td>
<td>United Kingdom</td>
<td>Cohort</td>
<td>Miscarriage, PTB, SGA, NICU admission, SARS-CoV-2 infection</td>
<td>None detected</td>
</tr>
</tbody>
</table>

Results from the 12 studies summarized show no increased risk of any poor obstetric outcome associated with COVID-19 vaccinations. The total number of participants included in these studies is 55,890. This has been calculated as the sum of all participants, except for those in Blakey et al. and Stock et al. who are also included in the UK Health Security Agency data and would otherwise be counted twice.

Male V. Nature Reviews, Immunology: 2022;22:277
<table>
<thead>
<tr>
<th>Main Benefits of COVID-19 Vaccination in Pregnancy</th>
<th>Main Risks of COVID-19 Vaccination in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduction in the risk of SARS-CoV-2 infection</td>
<td>Injection site pain</td>
</tr>
<tr>
<td>[10,25,38–45]</td>
<td>[24,25]</td>
</tr>
<tr>
<td>Reduction in the risk of severe SARS-CoV-2 infection</td>
<td>Fever</td>
</tr>
<tr>
<td>[25,38–44,46,47]</td>
<td>[24,25]</td>
</tr>
<tr>
<td>Reduction in the risk of COVID-19-related hospitalization</td>
<td>Rash</td>
</tr>
<tr>
<td>[10,25,38–45,47]</td>
<td>Fatigue</td>
</tr>
<tr>
<td>[24,25]</td>
<td>[24,25]</td>
</tr>
<tr>
<td>Reduction in the risk of ICU admission</td>
<td>Arthralgia</td>
</tr>
<tr>
<td>[25,38–44,47]</td>
<td>[24,25]</td>
</tr>
<tr>
<td>Reduction in the risk of maternal mortality</td>
<td>Myalgia</td>
</tr>
<tr>
<td>[25,38–44]</td>
<td>[24,25]</td>
</tr>
<tr>
<td>Decrease in stillbirth</td>
<td>Headache</td>
</tr>
<tr>
<td>[1,38,39,48]</td>
<td>[24,25]</td>
</tr>
<tr>
<td>Decrease in total preterm births</td>
<td></td>
</tr>
<tr>
<td>[43,48,49]</td>
<td></td>
</tr>
<tr>
<td>Reduction in the risk of SARS-CoV-2 infection in infants &lt;6 months</td>
<td>Nausea or vomiting</td>
</tr>
<tr>
<td>[50,51]</td>
<td>[24,25]</td>
</tr>
<tr>
<td>Reduction in the risk of severe SARS-CoV-2 infection in infants, including MIS-C</td>
<td>Chills</td>
</tr>
<tr>
<td>[3,52]</td>
<td>[24,25]</td>
</tr>
<tr>
<td>Reduction in the risk of hospitalization for COVID-19 in infants &lt;6 months</td>
<td>Lymphadenopathy</td>
</tr>
<tr>
<td>[17,25,40,43,53,54]</td>
<td>[24,25]</td>
</tr>
<tr>
<td>Reduction in the risk of ICU admission in infants &lt;6 months</td>
<td>Lymphadenitis</td>
</tr>
<tr>
<td>[3]</td>
<td>[24,25]</td>
</tr>
</tbody>
</table>

Julia-Burches C, Martinez-Varea A. J Personalized Med 2023;May
A population-based test-negative matched case control analysis of SARS-CoV-2 vaccine effectiveness among pregnant people in Ontario, Canada

**Methods:** Population-based matched test-negative case-control study of pregnant people aged 18–49 years, of 12 or more weeks’ gestation in Ontario, Canada, symptomatic with possible SARS-CoV-2 infection, and having at least one positive (n = 1842) or negative (n = 8524) rRT-PCR SARS-CoV-2 test between December 14, 2020 and December 31, 2021.

**Results:** In the primary outcome analysis, there were 1821 positive cases, matched to 1821 negative controls. The mean (SD) maternal age was 31 (5) years. When compared to those unvaccinated, receipt of ≥1 dose was associated with an estimated VE of 39% (95% CI 29–48%) for symptomatic infection, and 85% (95% CI 72–92%) for COVID-19 hospitalization. Vaccine effectiveness estimates demonstrated waning with increased time since last vaccination.

Associations of COVID-19 vaccination during pregnancy with adverse neonatal and maternal outcomes: A systematic review and meta-analysis

Forty-three observational studies were included. COVID-19 vaccination [96,384 (73.9%) BNT162b2, 30,889 (23.7%) mRNA-1273, and 3,172 (2.4%) other types] during pregnancy [23,721 (18.3%) in the first trimester, 52,778 (40.5%) in the second trimester, and 53,886 (41.2%) in the third trimester] was associated with reduced risks of stillbirth or neonatal death (OR, 0.74; 95% CI, 0.60–0.92). COVID-19 vaccination during pregnancy was not associated with congenital anomalies (OR, 0.83; 95% CI, 0.63–1.08), preterm birth (OR, 0.98; 95% CI, 0.90–1.06), NICU admission or hospitalization (OR, 0.94; 95% CI, 0.84–1.04), an Apgar score at 5 min <7 (OR, 0.93; 95% CI, 0.86–1.01), low birth weight (OR, 1.00; 95% CI, 0.88–1.14), miscarriage (OR, 0.99; 95% CI, 0.88–1.11), cesarean delivery (OR, 1.07; 95% CI, 0.96–1.19), or postpartum hemorrhage (OR, 0.91; 95% CI, 0.81–1.01).
Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis

Results: Among non-COVID-19 vaccines, the most frequent exposures were AS03 and aluminum-based adjuvants. A meta-analysis of studies that adjusted for potential confounders showed no association with adverse outcomes, regardless of the vaccine or the trimester of vaccination. Neither the reported rates of adverse pregnancy outcomes nor reactogenicity exceeded expected background rates, which was the case for AS03- or aluminum-adjuvanted non-COVID-19 vaccines in the proportion meta-analyses of uncontrolled studies/arms. The only exception was postpartum hemorrhage after COVID-19 vaccination (10.40%; 95% CI: 6.49–15.10%), reported by two studies; however, the comparison with non-exposed pregnant persons, available for one study, found non-statistically significant differences (adjusted OR 1.09; 95% CI 0.56–2.12). Animal studies showed consistent results with studies in pregnant persons.

Conclusion: We found no safety concerns for currently administered COVID-19 vaccines during pregnancy.

Ciapponi A, et al. Vaccine 2023;41:3688
The impact of COVID-19 vaccines on fertility: A systematic review and meta-analysis

Methods: PubMed, Scopus, Web of Science, Cochrane and Embase databases were searched for eligible studies until June 8th, 2022. The search was restricted to articles regarding humans, published in any languages, without additional restrictions.

Results: Out of 1406 studies screened, 29 were included in the systematic review. These studies, conducted in Israel (34.5%), USA (24.1%), Russia (20.7%), China (10.3%), Italy (3.5%), North America (3.5%) and Turkey (3.5%) were of poor (34.5%), moderate (58.6%) and good (6.9%) quality. Meta-analyses were performed for pre- and post-vaccination sperm progressive motility (44%, 95% CI 42%-62% vs 43%, 95% CI 31%-59% p = 0.07) and concentration (50.6 mln/ml, 95% CI 35.1–72.8 vs 55.4 mln/ml, 95% CI 37.4–82.2 p = 0.12). Biochemical (0.51, 95% CI 0.40–0.66 vs 0.60, 95% CI 0.53–0.68 p = 0.45) and clinical (0.45, 95% CI 0.37–0.54 vs 0.47, 95% CI 0.40–0.55 p = 0.31) pregnancy rate did not differ among vaccinated and not vaccinated groups. Subgroup meta-analyses based on the type of vaccine showed no significant difference: between vaccinated with mRNA vaccines and non-vaccinated regarding biochemical pregnancy rates; pre- and post-vaccination with Gam-COVID-Vac regarding testosterone, FSH and LH levels; pre- and post-vaccination with BNT162b2 vaccines regarding sperm volumes.

Conclusion: Based on the studies published so far, there is no scientific proof of any association between COVID-19 vaccines and fertility impairment in men or women.

• The American College of Obstetricians and Gynecologists (ACOG) strongly recommends that pregnant individuals be vaccinated against COVID-19.

• Vaccination may occur in any trimester, and emphasis should be on vaccine receipt as soon as possible to maximize maternal and fetal health.

• For patients who do not receive any COVID-19 vaccine, the discussion should be documented in the patient’s medical record. During subsequent office visits, obstetrician–gynecologists should address ongoing questions and concerns and offer vaccination again.

• COVID-19 vaccines may be administered simultaneously with other vaccines, including within 14 days of receipt of another vaccine. This includes vaccines routinely administered during pregnancy, such as the influenza and Tdap vaccines.
ACOG: COVID-19 Vaccines and Pregnancy: Key Messages

Risk Associated With COVID-19 Infection During Pregnancy

- COVID-19 infection during pregnancy is associated with increased risk of maternal severe illness, admission to an intensive care unit, mechanical ventilation, and death. There is increased risk of infection and death for certain racial and ethnic populations.
- There is a known increased risk of complications from COVID-19 in pregnant patients with underlying health conditions (e.g., diabetes, obesity, increasing age, and cardiovascular disease).
- There is an increased risk of preterm delivery, and there may be an increased risk of stillbirth.

Safety of COVID-19 Vaccines

- None of the COVID-19 vaccines available for use under emergency use authorization or U.S. Food and Drug Administration (FDA) license causes infertility or spontaneous abortion.
- There is no evidence of adverse maternal or fetal effects from vaccinating pregnant individuals with the COVID-19 vaccine, and a growing body of data demonstrates the safety of such use.

Efficacy of COVID-19 Vaccines

- The effectiveness of COVID-19 vaccines is similar in pregnant and non-pregnant individuals of similar age for prevention of COVID-19 infection and hospitalizations.
- All currently available COVID-19 vaccines have demonstrated high efficacy among their respective clinical trial endpoints.

Safety and Efficacy for the Newborn

- There are accumulating data demonstrating that antibodies are passed to the fetus when a pregnant person is vaccinated. gG antibodies after maternal vaccination in the third trimester have been shown in observational studies.

People who are pregnant are more likely to get very sick from COVID-19 compared to people who are not pregnant. People who get very sick from COVID-19 may require hospitalization, intensive care, or the use of a ventilator or special equipment to breathe. Severe COVID-19 illness can also lead to death. At increased risk of complications that can affect your pregnancy and developing baby. For example, COVID-19 during pregnancy increases the risk of delivering a preterm or stillborn infant.

Vaccination remains the best protection against COVID-19-related hospitalization and death. Getting the updated COVID-19 vaccine can protect you and others and is important to keep you and your developing baby as healthy as possible during pregnancy.

CDC recommends everyone ages 6 months and older get the updated COVID-19 vaccine. This includes people who are pregnant, breastfeeding, trying to get pregnant now, or those who might become pregnant in the future.

Studies including hundreds of thousands of people around the world show that COVID-19 vaccination before and during pregnancy is safe, effective, and beneficial to both the pregnant person and the baby. The benefits of receiving a COVID-19 vaccine outweigh any potential risks of vaccination during pregnancy.

Data show that mRNA COVID-19 vaccines during pregnancy are effective. They reduce the risk of severe illness and other health effects from COVID-19 for people who are pregnant. COVID-19 vaccination might also help prevent stillbirths and preterm delivery.

Receiving mRNA COVID-19 vaccines during pregnancy can help protect babies younger than age 6 months from hospitalization due to COVID-19.

Influenza, Tdap, and COVID-19 Vaccination Coverage and Hesitancy Among Pregnant Women, US, April 2023

Summary

What is already known about this topic?
Influenza, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap), and COVID-19 vaccines can reduce the risk for severe respiratory illness among pregnant women and their infants.

What is added by this report?
During the 2022–23 influenza season, 47.2% of women received influenza vaccination before or during pregnancy, 55.4% of women with a recent live birth received Tdap vaccination during pregnancy, and 27.3% of women received a COVID-19 bivalent booster vaccine before or during pregnancy. Pregnant women who received a provider recommendation for vaccination were less hesitant about influenza and Tdap vaccines.

What are the implications for public health practice?
Promotion of efforts to improve vaccination coverage among pregnant women, such as provider recommendation for vaccination and informative conversations with patients to address vaccine hesitancy, could reduce adverse maternal and infant illness and death from vaccine-preventable diseases.

FIGURE. Percentage of pregnant women* who were hesitant† about receiving influenza vaccine (A) and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (B) — Internet panel survey, United States, 2019–20 through 2022–23 influenza seasons

Razzaghi H, et al. MMWR 2023;72:1065

Summary
What is already known about this topic?
Among pregnant persons in the United States, Hispanic or Latino (Hispanic) and non-Hispanic Black or African American persons experience the highest COVID-19 rates and the lowest COVID-19 vaccination coverage. Aggregation of race and ethnicity data can obscure within-group diversity and inequities.

What is added by this report?
Among 102,275 Massachusetts residents with pregnancies resulting in live birth during May 2021–October 2022, data disaggregation into 12 racial and 34 ethnic groups revealed inequities in COVID-19 vaccination coverage that were masked within all larger race and ethnicity groupings.

What are the implications for public health practice?
Disaggregating race and ethnicity data can uncover within-group differences in COVID-19 vaccination coverage that might guide tailored public health messaging.


Meghani M, et al. MMWR 2023;72:1045 (29 Sept.)
CONCLUSIONS: COVID-19 VACCINATION AND PREGNANCY

Pregnant women are more prone to experience severe COVID-19 disease, including intensive care unit (ICU) admission, use of invasive ventilation, extracorporeal membrane oxygenation (ECMO), and mortality compared to non-pregnant individuals. Additionally, research suggests that SARS-CoV-2 infection during pregnancy is linked to adverse pregnancy outcomes, such as preterm birth, preeclampsia, and stillbirth, as well as adverse neonatal outcomes, including hospitalization and admission to the neonatal intensive care unit. This review assessed the available literature from November 2021 to 19 March 2023, concerning the safety and effectiveness of COVID-19 vaccination during pregnancy. COVID-19 vaccination administered during pregnancy is not linked to significant adverse events related to the vaccine or negative obstetric, fetal, or neonatal outcomes. Moreover, the vaccine has the same effectiveness in preventing severe COVID-19 disease in pregnant individuals as in the general population. Additionally, COVID-19 vaccination is the safest and most effective method for pregnant women to protect themselves and their newborns from severe COVID-19 disease, hospitalization, and ICU admission. Thus, vaccination should be recommended for pregnant patients. While the immunogenicity of vaccination in pregnancy appears to be similar to that in the general population, more research is needed to determine the optimal timing of vaccination during pregnancy for the benefit of the neonate.